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Abstract
Background: The role of n-3 fatty acids in prevention of breast cancer is well recognized, but the underlying
molecular mechanisms are still unclear. In view of the growing need for early detection of breast cancer, Graham
et al. (2010) studied the microarray gene expression in histologically normal epithelium of subjects with or without
breast cancer. We conducted a secondary analysis of this dataset with a focus on the genes (n = 47) involved in
fat and lipid metabolism. We used stepwise multivariate logistic regression analyses, volcano plots and false
discovery rates for association analyses. We also conducted meta-analyses of other microarray studies using
random effects models for three outcomes–risk of breast cancer (380 breast cancer patients and 240 normal
subjects), risk of metastasis (430 metastatic compared to 1104 non-metastatic breast cancers) and risk of recurrence
(484 recurring versus 890 non-recurring breast cancers).
Results: The HADHA gene [hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase
(trifunctional protein), alpha subunit] was significantly under-expressed in breast cancer; more so in those with
estrogen receptor-negative status. Our meta-analysis showed an 18.4%-26% reduction in HADHA expression in
breast cancer. Also, there was an inconclusive but consistent under-expression of HADHA in subjects with
metastatic and recurring breast cancers.
Conclusions: Involvement of mitochondria and the mitochondrial trifunctional protein (encoded by HADHA gene)
in breast carcinogenesis is known. Our results lend additional support to the possibility of this involvement. Further,
our results suggest that targeted subset analysis of large genome-based datasets can provide interesting
association signals.
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Background
Early detection of malignant breast neoplasms is critical
to cancer prevention and treatment. Cancer chemopre-
vention (also called as treatment of carcinogenesis) is a
primordial prevention step that is receiving considerable
attention. In that context, the identification of an ideal
biomarker for breast cancer has become increasingly
important. In spite of the vast number of studies con-
ducted in the past; a recent, comprehensive and elegant
review argues that there is still a lack of clarity regarding
the understanding of the process of breast carcinogenesis
[1]. Interestingly, it has been demonstrated that the
mammary gland basal cells have features consistent with
the progenitor stem cells and that they can differentiate
into benign or malignant lesions intraductally [2]. It has
also been shown in murine models that differentiated
intact mammary glands can exert a negative influence on
the development of breast cancer [3]. However, the
search for an ideal breast cancer biomarker is still on [4].
A logical undertaking in this direction is the use of
microarrays to study the differential gene expressions in
breast cancer. Consistent with the spirit of research that
encourages very early detection of carcinogenesis, Gra-
ham et al. [5] recently studied histologically normal
epithelium from subjects with and without breast cancer
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genomic change prior to carcinogenesis. They found
that many of these genes belonged to the family of
growth factors, cytokines, oxidative stress modifiers, p38
MAP kinase pathway members, transcription regulators
or determinants of nucleic acid stability [5].
Interestingly they did not find genes associated with
fatty acid or lipid metabolism to be differentially
expressed in histologically normal epithelium. Derange-
ments of fatty acid and lipid metabolism have been
implicated in oncogenesis in many studies, especially in
the cancer of breast [6]. It is generally believed that
diets rich in n-6 polyunsaturated fatty acids (n-6 PUFA)
and saturated fatty acids (SFA) increase the risk of
tumorigenesis while diets rich in n-3 polyunsaturated
fatty acids (n-3 PUFA) reduce the risk of cancer devel-
opment [7-10]. Lipids have the ability to influence the
process of neoplasia via their effects on hormone status,
cell membrane integrity, signal transduction, immune
modulation and regulation of gene expression [11,12].
In this study, we specifically examined whether the
genes related to fatty acid and lipid metabolism are also
differentially associated with breast cancer status. For
this, we used a targeted subset analysis of the microar-
r a yd a t af r o mG r a h a me ta l .[ 5 ]a n da l s oc o n d u c t e d
meta-analyses of other microarray datasets.
Methods
The primary dataset
The microarray dataset used in the present study is avail-
able for public use on the Gene Expression Omnibus
website http://www.ncbi.nlm.nih.gov/sites/GDSbrowser?
acc=GDS3716 of the National Institutes of Health, USA.
Details of the study subjects on whom these microarray
studies were conducted have been described previously
[5]. Briefly, the dataset comprises microarray data col-
lected through Affymetrix Human Genome U133A plat-
form that measures expression of 22,283 genes. The data
were collected using histologically normal epithelium
from four sets of subjects–those who underwent reduc-
tion mammoplasty (n = 18), those who underwent pre-
ventive mastectomy (n = 6), estrogen receptor positive
(ER+) breast cancer patients (n = 9) and estrogen recep-
tor negative (ER-) breast cancer patients (n = 9). The
data were available in normalized format.
Targeted subset analysis
Our main aim was to assess if genes related with fatty
acid and lipid metabolism were differentially expressed
in the study dataset. For this we first culled a list of
genes that have been implicated in the fatty acid and
lipid metabolism. We used the DAVID http://david.
abcc.ncifcrf.gov and KEGG Pathway http://www.genome.
jp/kegg/metabolism.html websites and generated a list of
136 genes implicated in one or more of the following
pathways: fatty acid metabolism, fatty acid biosynthesis,
peroxisome proliferator-activated receptor (PPAR) sig-
naling pathway, lipopolysaccharide biosynthesis, lipid
metabolism and fat digestion and absorption. A full list
with functional annotation of these 136 genes is pro-
vided as Additional file 1: Table S1. We then used the
DAVID http://david.abcc.ncifcrf.gov and Clone/Gene ID
Converter http://idconverter.bioinfo.cnio.es/IDconverter.
p h pp r o g r a m st of i n do u tw h i c ho ft h e s e1 3 6g e n e s
were included in the Affymetrix Human Genome
U133A platform. We found 47 probe sets related to
genes (Table 1) that partake in lipid or fatty acid meta-
bolism to be represented in the study datasets. We con-
ducted our analyses on the potential differential
expression of these 47 genes. Complete functional anno-
tation for these 47 genes is provided in Additional file 2:
Table S2.
Replication of the results: meta-analyses
We also aimed to ensure that the results obtained from
one microarray dataset were robust and could be repli-
cated in other datasets. We queried the Oncomine data-
base and retrieved microarray data from other relevant
studies. We studied the association of gene expression
with three outcomes–risk of breast cancer, risk of
metastasis and risk of recurrence. We then combined
these datasets meta-analytically using the random effects
model of DerSimonian and Laird [13,14]. For these ana-
lyses the effect size was measured and expressed as the
standardized mean difference (SMD) and its 95% confi-
dence intervals. The Oncomine website reports the
r e s u l t sa sm e a n s ,m e d i a n s ,q u a r t i l e sa n dm i n i m u ma n d
maximum values. Since the random-effects model
assumes normal distribution of the effect measures, we
first estimated the mean and standard error for each
group (for example, for subjects with breast cancer; sub-
jects with a metastatic event or subjects with recurring
breast cancer) using the method described by Hozo et
al. [15] We then estimated the SMDs. To depict the
potential variability in the HADHA expression based on
the probes used by individual studies, we conducted the
meta-analyses separately for each combination of the
study and the probe used. Each comparison represented
a specific combination of the included study and the
reporter used in the study. The between-study heteroge-
neity in this meta-analysis was examined using the I
2
statistic. Since expression data on all individual subjects
was available for the outcome of risk of breast cancer,
we also conducted individual patient data (IPD) meta-
analysis [16]. For this we used the clustered uncondi-
tional logistic regression analyses [16,17] with disease
status as a dichotomous dependent variable, compari-
son-specific z-scores as the predictor variable and
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# Symbol Affymetrix Probe
Set Id
Gene Name
1 ACAA1 202025_x_at acetyl-Coenzyme A acyltransferase 1
2 ACADL 206068_s_at acyl-Coenzyme A dehydrogenase, long chain
3 ACADM 202502_at acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain
4 ACAT1 205412_at acetyl-Coenzyme A acetyltransferase 1
5 ACSBG2 221716_s_at acyl-CoA synthetase bubblegum family member 2
6 ACSL3 201660_at acyl-CoA synthetase long-chain family member 3
7 ACSL4 202422_s_at acyl-CoA synthetase long-chain family member 4
8 ACSL5 218322_s_at acyl-CoA synthetase long-chain family member 5
9 ADH1A 207820_at alcohol dehydrogenase 1B (class I), beta polypeptide; alcohol dehydrogenase 1A (class I), alpha polypeptide;
alcohol dehydrogenase 1C (class I), gamma polypeptide
10 ADH6 207544_s_at alcohol dehydrogenase 6 (class V)
11 ADIPOQ 207175_at adiponectin, C1Q and collagen domain containing
12 AGPAT2 210678_s_at 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta)
13 ANGPTL4 221009_s_at angiopoietin-like 4
14 APOA4 206894_at apolipoprotein A-IV
15 APOC3 205820_s_at apolipoprotein C-III
16 AQP7 206955_at aquaporin 7
17 ARSA 204443_at arylsulfatase A
18 ASAH1 210980_s_at N-acylsphingosine amidohydrolase (acid ceramidase) 1
19 CERK 218421_at ceramide kinase
20 CETP 206210_s_at cholesteryl ester transfer protein, plasma
21 CYP7A1 207406_at cytochrome P450, family 7, subfamily A, polypeptide 1
22 DGAT1 202344_at diacylglycerol O-acyltransferase homolog 1 (mouse)
23 EHHADH 205222_at enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase
24 FABP2 207475_at fatty acid binding protein 2, intestinal
25 FUT2 208505_s_at fucosyltransferase 2 (secretor status included)
26 FUT4 209892_at fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
27 FUT5 210398_x_at fucosyltransferase 5 (alpha (1,3) fucosyltransferase)
28 FUT9 207696_at fucosyltransferase 9 (alpha (1,3) fucosyltransferase)
29 GCDH 203500_at glutaryl-Coenzyme A dehydrogenase
30 GK2 215430_at glycerol kinase 2
31 GLA 214430_at galactosidase, alpha
32 HADHA 208629_s_at hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase
(trifunctional protein), alpha subunit
33 LTA 206975_at lymphotoxin alpha (TNF superfamily, member 1)
34 MTTP 205675_at microsomal triglyceride transfer protein
35 NPC1L1 220106_at NPC1 (Niemann-Pick disease, type C1, gene)-like 1
36 NR1H3 203920_at nuclear receptor subfamily 1, group H, member 3
37 OLR1 210004_at oxidized low density lipoprotein (lectin-like) receptor 1
38 PCK2 202847_at phosphoenolpyruvate carboxykinase 2 (mitochondrial)
39 PLTP 200661_at phospholipid transfer protein
40 PPARG 208510_s_at peroxisome proliferator-activated receptor gamma
41 RXRB 209148_at retinoid × receptor, beta
42 RXRG 205954_at retinoid × receptor, gamma
43 SGMS1 212989_at sphingomyelin synthase 1
44 ST8SIA1 210073_at ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1
45 UCP1 221384_at uncoupling protein 1 (mitochondrial, proton carrier)
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ison-specific z-scores were estimated as the relative
deviates (mean expression/standard deviation of expres-
sion) within each comparison group.
Other statistical analysis
To quantify and test differential gene expression, we
used two-tailed Student’s t tests for unpaired samples.
The clinical and statistical significance of the findings
were presented as volcano plots. To account for multi-
p l et e s t i n g ,w ee s t i m a t e dt h ef a l s ed i s c o v e r yr a t e s( q
values) using the QVALITY software program [18]. Dis-
criminant utility of each gene was assessed using non-
parametric receiver operating characteristic (ROC) curve
analysis. To group subjects based on their HADHA
expression, we used a k-means clustering approach. All
statistical analyses were conducted using Stata 10.0 soft-
ware package (Stata Corp, College Station, Texas). We
aimed for a type I error rate of 0.05 and a false discov-
ery rate of 0.15.
Results
Differential expression analyses
Using the shortlisted set of 47 genes shown in Table 1,
w ef i r s td e t e r m i n e di ft h e s egenes were differentially
expressed in subjects with cancer (n = 18) and those
without (n = 24). The volcano plot (Figure 1A) showed
that seven of the 47 genes were significantly differentially
expressed between these study groups. These genes
included five over-expressed genes (AQP7, PLTP, PCK2,
GCDH and ARSA) and two under-expressed genes
(ACSL5 and HADHA). Of these, HADHA was the most
significant statistically. To account for the possible covar-
iance among these gene expression values we conducted
stepwise multivariate analyses using unconditional logis-
tic regression and observed that only two genes–HADHA
and ARSA–were retained in the final model (Figure 1B).
This model explained 35% of inter-individual variability
in breast cancer susceptibility with a predictive accuracy
of 86.8%. Interestingly, when HADHA expression was
removed from this model the ARSA lost its statistical sig-
nificance but removal of ARSA did not affect the statisti-
cal significance of HADHA. This indicates that HADHA
gene expression was the most important statistical pre-
dictor of altered risk of breast cancer.
Does ER status influence the expression of HADHA?
To examine if this association could be influenced by
the ER status, we conducted three sets of analyses. First,
we studied whether HADHA expression was different
based on the ER status. We found that the mean
HADHA was not significantly differentially expressed by
ER status (mean HADHA expression in subjects with ER
+ breast cancer = 6.00; in subjects with ER-breast cancer
=5 . 9 0 ;p = 0.462). Second, we adjusted the standard
error estimates for the ER status using clustered logistic
regression and observed that the statistical significance
for the HADHA gene expression further increased (p =
0.0001) while that of the ARSA gene decreased (p =
0.082) indicating that the association of HADHA was
unlikely to have been influenced by the ER status.
Third, we constructed volcano plots and conducted
stepwise logistic regression analyses by comparing the
ER + and ER-subjects separately with subjects without
cancer as the reference group. We observed (Figure 1C-
F) that HADHA gene expression was the only consistent
predictor across ER status but more so in the ER-sub-
jects. Indeed, the q value for the HADHA gene was 0.15
for the cancer versus no cancer comparison, 0.13 for the
ER-versus no cancer comparison but 0.88 for the ER +
versus no cancer comparison. Two other genes (UCP3
and DGAT1) were retained in the final model of step-
wise regression analyses when ER-subjects were com-
pared to the no cancer group however this association
was not observed when ER + subjects were compared to
the same reference group.
Graded risk of breast cancer based on HADHA expression
We next considered whether the association of HADHA
gene expression with risk of breast cancer exhibited a
threshold effect or whether it was a graded dose-
response. For this, we used two approaches. First, we
normalized the gene expression in the no cancer group
to 100%. We found (Figure 1G) that the HADHA
expression had fallen to 73% (95% CI 64%-83%) in sub-
jects with cancer; with a higher expression in ER + sub-
jects (76% of the no cancer group, 95% CI 61%-91%)
than in ER-subjects (70% of the no cancer group, 95%
CI 55%-85%). Second, the k-means clusters (which
explained 95.9% of the variability in HADHA expression)
clearly demonstrated a dose-response association (Figure
1H) such that more severe down-regulation of HADHA
was associated with a greater risk of being in the breast
cancer group.
Meta-analyses of the differential expression of HADHA
Lastly, we examined the robustness of the differential
expression of HADHA by conducting meta-analysis of
Table 1 Genes included in the analyses (Continued)
46 UCP3 207349_s_at uncoupling protein 3 (mitochondrial, proton carrier)
47 UGCG 204881_s_at UDP-glucose ceramide glucosyltransferase
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Figure 1 Association of fatty acid and lipid metabolism related genes with the risk of breast cancer. (A-F) Association analyses. Panels
A, C and E show the volcano plots for cancer with no cancer, ER-versus no cancer and ER + versus no cancer comparisons, respectively. These
plots depict the biological significance (log-fold change) on the X-axis and the statistical significance (-log P) on the Y-axis. Significance values
above 0.1 are indicated by the grey shaded area in the volcano plots. Panels, B, D and F show the corresponding receiver-operating
characteristic (ROC) curves for the final models from stepwise logistic regression analyses. The genes retained in the final model and their
statistical significance is shown under the ROC curves, the variance explained by the model is shown as R
2 and the predictive accuracy is
indicated by the area under the ROC curve (AUC). (G) Comparative expression of the HADHA gene in the indicated study groups. Error bars
indicate 95% confidence intervals. (H) Bubble plot showing the dose-response relationship between HADHA expression and the risk of breast
cancer. Each bubble represents one of the six clusters generated using k-means clustering algorithm based on the HADHA expression. The radius
of the bubble is proportional to the number of subjects in that cluster (indicated by numbers next to the bubbles).
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Page 5 of 11published microarray studies comparing cases of breast
cancer with subjects without breast cancer. Querying
the Oncomine database, we found six studies [19-24]
that represented 20 different comparisons of breast can-
cer patients with normal subjects (Table 2). The reasons
for this larger number of comparisons were the different
reporters used in the microarray experiments as well as
the different subtypes of breast cancer reported by the
studies.
We first observed that the mean expression levels for
HADHA probes (expressed as log transformed values)
were widely different across the six studies (Zhao et al.
[24]:-0.33, Radvanyi et al. [21]: 3.08, Richardson et al.
[22]: 5.29, Karnoub et al. [20]: 2.97, Turashvili et al.
[23]: 3.92 and Finak et al. [19]:-2.65). We therefore
transformed these values into comparison-specific z-
scores (mean expression for a comparison/standard
deviation of expression for that comparison). Upon this
z-transformation, all the studies had a mean z-score of 0
and a standard deviation of 1. We conducted meta-ana-
lyses on the HADHA expression z-scores. Using the
DerSimonian and Laird model, we observed (Figure 2)
that the summary SMD (filled diamond in Figure 2)
was-0.48 (95% CI-0.84–0.11). Considering the statistical
properties of SMD it is possible to transform this into
probability [25]. This transformation indicated that
there was an average 18.4% reduction in expression of
HADHA (95% CI 4.5%-30.0%) in cases of breast cancer
as compared to normal subjects. Interestingly, this sig-
nificant reduction in the expression of HADHA was
observed in spite of the high degree of heterogeneity (I
2
64.6, p < 0.001, pie-chart in Figure 2) between the com-
parisons due to different cancer subtypes, reporters used
in various studies and other study characteristics.
We observed that the invasive ductal carcinoma (p =
0.046) and unspecified invasive breast carcinoma (p =
0.005) showed a significant under-expression of HADHA
gene but lobular carcinoma (p = 0.781), invasive lobular
carcinoma (p = 0.780) or invasive mixed carcinoma (p =
0.717) did not show a significant alteration of HADHA
gene expression. Alternatively, we conducted the IPD
meta-analysis using logistic regression analyses. We
found that the odds ratio for breast cancer was 0.74
(95% CI 0.60-0.92) after clustered analyses. Thus, there
was a 26% reduction in the risk of breast cancer per
unit increase in z-scores. These values show a striking
resemblance with the findings observed in the Graham
et al. dataset and demonstrate the replicability of our
findings.
We also investigated if HADHA expression was asso-
ciated with an altered risk of metastasis and recurrence.
For risk of a metastatic event we found nine studies
[26-33] representing 430 metastatic events and 1104
metastasis-free cancers (Figure 3). Subjects who devel-
oped a metastatic event during follow-up had a reduced
HADHA expression (summary effect size-0.65, 95% CI-
Table 2 Comparisons included in the meta-analysis of differential HADHA expression
No Author, Year Ref Controls Cases Breast cancer histology Reporter
1 Zhao, 2004 [24] 3 37 Invasive ductal carcinoma IMAGE:1473300
2 Zhao, 2004 [24] 3 21 Lobular carcinoma IMAGE:1473300
3 Radvanyi, 2005 [21] 9 7 Invasive lobular carcinoma BE297873
4 Radvanyi, 2005 [21] 9 32 Invasive ductal carcinoma BE297873
5 Radvanyi, 2005 [21] 9 3 Invasive mixed carcinoma BE297873
6 Radvanyi, 2005 [21] 9 3 Ductal carcinoma in situ BE297873
7 Richardson, 2006 [22] 7 40 Ductal carcinoma 208629_s_at
8 Richardson, 2006 [22] 7 40 Ductal carcinoma 208630_at
9 Richardson, 2006 [22] 7 40 Ductal carcinoma 208631_s_at
10 Karnoub, 2007 [20] 15 7 Invasive ductal carcinoma 208629_s_at
11 Karnoub, 2007 [20] 15 7 Invasive ductal carcinoma 208630_at
12 Karnoub, 2007 [20] 15 7 Invasive ductal carcinoma 208631_s_at
13 Turashvili, 2007 [23] 20 5 Invasive ductal carcinoma 208629_s_at
14 Turashvili, 2007 [23] 20 5 Invasive ductal carcinoma 208629_s_at
15 Turashvili, 2007 [23] 20 5 Invasive ductal carcinoma 208630_at
16 Turashvili, 2007 [23] 20 5 Invasive lobular carcinoma 208630_at
17 Turashvili, 2007 [23] 20 5 Invasive lobular carcinoma 208631_s_at
18 Turashvili, 2007 [23] 20 5 Invasive lobular carcinoma 208631_s_at
19 Finak, 2008 [19] 6 53 Invasive breast carcinoma A_24_P242688
20 Finak, 2008 [19] 6 53 Invasive breast carcinoma A_24_P353964
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Page 6 of 111.47-0.16) but this was not statistically significant (p =
0 . 1 1 7 ) .A l s o ,t h e r ew a sav e r yh i g hd e g r e eo fb e t w e e n -
study heterogeneity (I
2 98.8%). Similarly, for the out-
come of the risk of recurrence (Figure 4), we found that
there were 10 studies [19,27,29,30,32,34-38] representing
484 recurring and 890 non-recurring breast cancers.
Meta-analysis demonstrated that although there was a
consistent decrease in average HADHA expression in
patients with a recurring form of breast cancer (sum-
mary effect size-0.60, 95% CI-1.44-0.24), the finding was
neither statistically significant (p =0 . 1 6 0 )n o rh o m o g e -
neous (I
2 = 98.7%) across studies.
Discussion
Our analyses of the microarray dataset based on the
Graham et al. [5] study demonstrated a consistent,
strong and significant association of the HADHA gene
expression in histologically normal epithelium with the
likelihood of breast cancer. Moreover, this observation
was further substantiated by the meta-analysis of other
published studies. Only one study has previously
reported differential association of this gene with regard
to BRCA1 positive, BRCA2 positive and sporadic malig-
nant tumors of the breast [39]. Our results further sup-
port the putative involvement of HADHA in breast
cancer susceptibility.
Biological plausibility
Biological significance of our novel observations should
be considered in the light of the following facts. First, the
HADHA gene (chromosomal location 2p23) codes for the
four alpha chains in the 8-meric mitochondrial trifunc-
tional protein (TFP) [40]. This enzyme performs three
cardinal functions in the b-oxidation of long chain fatty
acids by catalyzing the activities of the 2-enoyl-CoA
hydratase (ECH), L-3-hydroxyacyl-CoA dehydrogenase
Overall (Conventional meta-analysis)
Turashvili, 2007; 208629_s_at
Finak, 2008; A_24_P353964
Turashvili, 2007; 208631_s_at
Finak, 2008; A_24_P242688
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Richardson, 2006; 208631_s_at
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Karnoub, 2007; 208629_s_at
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0.07 (-0.91, 1.05)
-1.38 (-2.26, -0.50)
-0.49 (-1.49, 0.50)
-2.88 (-3.88, -1.89)
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-0.23 (-1.21, 0.75)
-1.22 (-2.06, -0.38)
0.18 (-0.81, 1.17)
0.16 (-0.82, 1.14)
SMD (95% CI)
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-0.80 (-1.80, 0.21)
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Figure 2 Meta-analysis of the differential expression of the HADHA gene in breast cancer compared to subjects without breast cancer.
The figure shows a forest plot with filled diamonds indicating the point estimates and error bars indicating the 95% confidence interval around
the standardized mean difference. The summary effect measure is shown as a filled diamond whose center (dashed vertical line) indicates the
point estimate and the width indicates the 95% confidence interval.
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Page 7 of 11(HACD) and 3-ketoacyl-CoA thiolase (KACT). Of these
three, the first two enzymes (ECH and HACD) are speci-
fically catalyzed by the alpha chains of TFP. Severe defi-
ciency (< 50% of normal activity) of TFP is known to be
associated with life-threatening manifestation of the long
chain 3-hydroxyacyl-CoA dehydrogenase deficiency [41].
However, the effects of a milder deficiency of TFP (for
example, activity between 50%-80% of the normal) are
currently unknown. Our results indicate that breast can-
cer patients had 18-30% decreased expression of HADHA
gene. We therefore hypothesize that there may be a com-
promised metabolism of long chain fatty acids in breast
cancer due to a relative deficiency of the alpha chains of
TFP. In this context, it is noteworthy that a recent large
genome-wide association study [42] found a strong asso-
ciation of breast cancer with a polymorphism in the gene
encoding enoyl CoA hydratase domain containing 1
(ECHDC1), which also partakes in the integrity of the
TFP.
Second, the efficacy of b-oxidation of n-3 and n-6
long chain fatty acids can be tissue- and location- speci-
fic. For example, in rat livers it has been shown that the
n-3/n-6 ratio influences peroxisomal but not mitochon-
drial b-oxidation [43]. In contrast, mitochondrial b-oxi-
dation of long chain fatty acid has been implicated in
breast cancer pathogenesis [42]. We also could not
demonstrate a significant association of the genes
involved in the PPAR-g pathway reinforcing the possibi-
lity that mitochondrial rather than peroxisomal b-oxida-
tion of long chain fatty acids may be more critical in
breast carcinogenesis. Third, HADHA occupies an
important position in the network of genes that have
been implicated in autophagy and apoptosis [44]. Finally,
triangulation of the following facts lends additional cre-
dence to our observations: i) intact epithelium of mam-
mary glands has the ability to act as stem cells for
carcinogenesis [2]; ii) n-3 long chain fatty acids have the
ability to target such stem cells [45]; and iii) HADHA is
Author, year; reporter SMD (95% CI) Weight SMD (95% CI)
Overall 
Kao et al, 2011; 208629_at
Schmidt et al, 2008; 208630_at
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Loi et al, 2008; 208631_s_at
Loi et al, 2008; 208630_at
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Schmidt et al, 2008; 208629_s_at
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Chin et al, 2007; 02-026274052
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Figure 3 Meta-analysis of the differential expression of the HADHA gene in breast cancer patients with and without metastatic events.
The figure shows a forest plot with filled diamonds indicating the point estimates and error bars indicating the 95% confidence interval around
the standardized mean difference. The summary effect measure is shown as a hollow diamond whose center (dashed vertical line) indicates the
point estimate and the width indicates the 95% confidence interval.
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Page 8 of 11involved in the mitochondrial b-oxidation of long chain
fatty acids. Together these observations from published
literature strongly support the biological plausibility of
our finding that HADHA is differentially expressed in
subjects with and without breast cancer.
Limitations
Our study has all the limitations implicit in any micro-
array association study and meta-analyses. In addition,
there are three more limitations. First, although there is
a strong circumstantial evidence that favors an inference
of HADHA expression-breast cancer association, it must
be realized that robust functional studies are required
before this association can be conclusively claimed. Our
study does not have a component of functional assays
that can help put these results in a biological perspec-
tive. Second, due to limitations imposed by the microar-
r a yp l a t f o r mu s e di nt h ep r i m a r ys t u d y ,w ec o u l dn o t
evaluate the potential association of a large number of
additional lipid and fat metabolism related genes with
the risk of breast cancer. Inclusion of those genes may
not only affect the q values associated with HADHA but
also may provide a more comprehensive understanding
of the role of fatty acids in breast cancer. Thirdly,
although consistent, the observed differential expression
of HADHA with cancer progression (as reflected by risk
of metastasis and recurrence) is statistically inconclusive.
Conclusions
Our study has three important implications–biological,
methodological and epidemiologic. Biologically, our
study has identified a novel target gene that corrobo-
rates the existing knowledge about the role of long
chain fatty acids in breast cancer and provides interest-
ing directions for further research in this area. Also, our
findings put the focus on the putative functional aspects
of mitochondria and TFP in breast carcinogenesis.
From a methodological standpoint, our study shows
that high dimensionality of omics-type datasets is
fraught with the vexing problem of finding strong
Author, year; reporter SMD (95% CI) Weight SMD (95% CI)
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Figure 4 Meta-analysis of the differential expression of the HADHA gene in breast cancer patients with and without recurrence
events. The figure shows a forest plot with filled diamonds indicating the point estimates and error bars indicating the 95% confidence interval
around the standardized mean difference. The summary effect measure is shown as a hollow diamond whose center (dashed vertical line)
indicates the point estimate and the width indicates the 95% confidence interval.
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Page 9 of 11associations at the cost of potentially missing weaker but
biologically meaningful associations. Literature addres-
s i n gt h ei s s u eo fm u l t i p l ec o m p a r i s o n si nl a r g ev o l u m e
datasets focuses primarily on the possibility of finding
false positive associations [46]. However, there exists a
demonstrable probability that such high-volume datasets
may also falsely mask true associations. It is likely that
t h eG r a h a me ta l .s t u d yd i dn o tr e p o r tas i g n i f i c a n t
association of HADHA with the risk of breast cancer
due to a large number of multiple comparisons. The
fact that we discovered an association of HADHA with
breast cancer shows that microarray dataset analysis (as
well as analyses of other large datasets like genome-wide
association studies, proteomics data or metabolomics
datasets) may benefit by using targeted subset analyses
based on functional annotation and conceptual under-
standing of the molecular mechanisms in disease.
Finally, in an epidemiological context, our study shows
that error in long chain fatty acid metabolism in the
breast tissue might herald the onset of carcinogenesis
and thus can be helpful for the primordial prevention of
breast cancer.
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